Email this article Innovations in the therapy of oncohematological diseases
- Issue: Vol 24, No 2 (2022)
- Pages: 142-148
- Section: CLINICAL ONCOLOGY
- URL: https://ogarev-online.ru/1815-1434/article/view/109357
- DOI: https://doi.org/10.26442/18151434.2022.2.201696
- ID: 109357
Cite item
Full Text
Abstract
On March 26, 2022, the First scientific and practical forum of the biopharmaceutical company Nanolek was held, dedicated to the issues of modern methods for the treatment of lymphoproliferative diseases using innovative targeted drugs, including Bruton tyrosine kinase inhibitor – zanubrutinib. The leading Russian speakers showed the results of new clinical studies in the context of therapy of mantle cell lymphoma, Waldenstrom's disease, marginal zone lymphoma, as well as chronic lymphocytic leukemia. The algorithms for the management of patients, as well as the complex issues concerning the choosing therapy in case of relapses of non-Hodgkin lymphomas and chronic lymphocytic leukemia were discussed.
Full Text
##article.viewOnOriginalSite##Supplementary files
Supplementary Files
Action
1.
JATS XML
2.
Fig. 1. Progression-free survival (PFS) and overall survival (OS) in patients with mantle cell lymphoma (MCL).
Download (153KB)
3.
Fig. 2. PFS and OS in patients with relapsed/refractory (R/R) MCL receiving zanubrutinib in the BGB-3111-206 study.
Download (182KB)
4.
Fig. 3. The efficacy of zanubrutinib in R/R MCL patients with a TP53 mutation.
Download (59KB)
5.
Fig. 4. The characteristics of patients within the framework of the ALPINE study.
Download (70KB)
6.
Fig. 5. Cumulative frequency of atrial fibrillation/flutter (AF/AFL).
Download (76KB)
7.
Fig. 6. The immediate efficacy of zanubrutinib in case of marginal zone lymphoma (MZL) within the framework of the MAGNOLIA trial.
Download (56KB)
8.
Fig. 7. The duration of response and PFS within the framework of the MAGNOLIA trial.
Download (114KB)
9.
Fig. 8. The immediate efficacy within the framework of the ASPEN study.
Download (68KB)
10.
Fig. 9. Event-free survival in patients within the framework of the ASPEN study.
Download (104KB)
11.
Fig. 10. The time to first AF/AFL within the framework of the ASPEN study.
Download (92KB)
12.
Fig. 11. The selectivity of zanubrutinib and ibrutinib.
Download (117KB)
13.
Fig. 12. The frequency of AE during zanubrutinib therapy.
Download (94KB)
